Effectiveness and Safety of Valsartan in Children Aged 6 to 16 Years With Hypertension

Effectiveness and Safety of Valsartan in Children Aged 6 to 16 Years With Hypertension

The effectiveness and safety of valsartan have not been assessed in hypertensive children. Therefore, hypertensive patients aged 6 to 16 years (n=261) were randomized to receive weight‐stratified low‐ (10/20 mg), medium‐ (40/80 mg), or high‐dose (80/160 mg) valsartan for 2 weeks. After 2 weeks, pati...

Cur síos iomlán

Sábháilte in:

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Thomas G. Wells, Jeffrey L. Blumer, Kevin Meyers, Jose Pacheco Neto, Rejane de Paula Meneses, Mieczysław Litwin, Johan Vande Walle, Susan Solar‐Yohay, Victor Shi, Guangyang Han
Formáid:	Artigo
Teanga:	Béarla
Foilsithe / Cruthaithe:	2011
Rochtain ar líne:	https://doi.org/10.1111/j.1751-7176.2011.00432.x
Clibeanna:	Cuir clib leis Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!

Míreanna comhchosúla

Effectiveness and Safety of Valsartan in Children Aged 6 to 16 Years With Hypertension
de réir: Wells, Thomas, et al.
Foilsithe / Cruthaithe: (2011)

The Efficacy and Safety of Valsartan in Obese and Non‐Obese Pediatric Hypertensive Patients
de réir: Meyers, Kevin E. C., et al.
Foilsithe / Cruthaithe: (2011)

Efficacy and Safety of the Angiotensin Receptor Blocker Valsartan in Children With Hypertension Aged 1 to 5 Years
de réir: Joseph T. Flynn, et al.
Foilsithe / Cruthaithe: (2008)

Efficacy and Safety of Valsartan or Chlorthalidone vs. Combined Valsartan and Chlorthalidone in Patients With Mild to Moderate Hypertension: The VACLOR Study
de réir: Manzur, Fernando, et al.
Foilsithe / Cruthaithe: (2018)

Clinical and Demographic Characteristics of Children With Hypertension
de réir: Joseph T. Flynn, et al.
Foilsithe / Cruthaithe: (2012)

Evaluation of the Dose Response With Valsartan and Valsartan/Hydrochlorothiazide in Patients With Essential Hypertension
de réir: Weir, Matthew R., et al.
Foilsithe / Cruthaithe: (2007)

Why should we screen for arterial hypertension in children and adolescents?
de réir: Litwin, Mieczysław
Foilsithe / Cruthaithe: (2017)

Randomized Study of Antihypertensive Efficacy and Safety of Combination Aliskiren/Valsartan vs Valsartan Monotherapy in Hypertensive Participants With Type 2 Diabetes Mellitus
de réir: Bakris, George L., et al.
Foilsithe / Cruthaithe: (2012)

Origins of Primary Hypertension in Children
de réir: Mieczysław Litwin, et al.
Foilsithe / Cruthaithe: (2020)

Obesity, metabolic syndrome, and primary hypertension
de réir: Litwin, Mieczysław, et al.
Foilsithe / Cruthaithe: (2020)

Obesity, metabolic syndrome, and primary hypertension
de réir: Mieczysław Litwin, et al.
Foilsithe / Cruthaithe: (2020)

Effectiveness and safety of valsartan/amlodipine in hypertensive patients with stroke: China Status II subanalysis
de réir: Zhang, Weiliang, et al.
Foilsithe / Cruthaithe: (2017)

Long-term safety and tolerability of valsartan in children aged 6 to 17 years with hypertension
de réir: Lou-Meda, Randall, et al.
Foilsithe / Cruthaithe: (2018)

Aliskiren and valsartan combination therapy for the management of hypertension
de réir: Epstein, Benjamin J
Foilsithe / Cruthaithe: (2010)

A child presenting with severe hypertension and circulatory failure—a diagnostic conundrum: Answers
de réir: Keenswijk, Werner, et al.
Foilsithe / Cruthaithe: (2017)

Comparative Efficacy of Aliskiren/Valsartan vs Valsartan in Nocturnal Dipper and Nondipper Hypertensive Patients: A Pooled Analysis
de réir: Giles, Thomas D., et al.
Foilsithe / Cruthaithe: (2012)

Clinical utility of valsartan in the treatment of hypertension in children and adolescents
de réir: Baracco, Rossana, et al.
Foilsithe / Cruthaithe: (2011)

Benefits and pitfalls of sacubitril/valsartan treatment in patients with hypertension
de réir: Chrysant, Steven G.
Foilsithe / Cruthaithe: (2018)

Sacubitril/valsartan: evaluation of safety and efficacy as an antihypertensive treatment
de réir: Anderson, Sarah L, et al.
Foilsithe / Cruthaithe: (2018)

Primary Hypertension in Children and Adolescents is an Immuno-Metabolic Disease with Hemodynamic Consequences
de réir: Litwin, Mieczysław, et al.
Foilsithe / Cruthaithe: (2013)

VALSARTAN REGULATES MYOCARDIAL AUTOPHAGY AND MITOCHONDRIAL TURNOVER IN EXPERIMENTAL HYPERTENSION
de réir: Zhang, Xin, et al.
Foilsithe / Cruthaithe: (2014)

Efficacy of amlodipine besylate and Valsartan for the treatment of mild to moderate hypertension
de réir: Wang, Xiao-ou, et al.
Foilsithe / Cruthaithe: (2019)

The effects of sacubitril/valsartan and ramipril on the male fertility in hypertensive rats
de réir: Aykan, Duygun Altintas, et al.
Foilsithe / Cruthaithe: (2020)

Addition of Amlodipine or Valsartan for Improvement of Diastolic Dysfunction Associated with Hypertension
de réir: Oh, Jin Kyung, et al.
Foilsithe / Cruthaithe: (2020)

Sacubitril/Valsartan in the Treatment of Resistant Hypertension: Raising Star or Illusion?
de réir: Tadic, Marijana, et al.
Foilsithe / Cruthaithe: (2022)

Valsartan Regulates Myocardial Autophagy and Mitochondrial Turnover in Experimental Hypertension
de réir: Xin Zhang, et al.
Foilsithe / Cruthaithe: (2014)

Evaluation of effectiveness and safety of amlodipine/valsartan/hydrochlorothiazide single-pill combination therapy in hypertensive patients: an observational study
de réir: Hagendorff, Andreas, et al.
Foilsithe / Cruthaithe: (2014)

Efficacy and Safety of Valsartan/Amlodipine Single-Pill Combination in 11,422 Chinese Patients with Hypertension: an Observational Study
de réir: Hu, Dayi, et al.
Foilsithe / Cruthaithe: (2014)

Evaluation of effectiveness and safety of amlodipine/valsartan/hydrochlorothiazide single-pill combination therapy in hypertensive patients: an observational study
de réir: Andreas Hagendorff, et al.
Foilsithe / Cruthaithe: (2014)

Sacubitril/Valsartan
de réir: Kieran F. Docherty, et al.
Foilsithe / Cruthaithe: (2020)

Blood Pressure Rhythmicity and Visceral Fat in Children With Hypertension
de réir: Anna Niemirska, et al.
Foilsithe / Cruthaithe: (2013)

Efficacy and safety of valsartan plus hydroclorothiazide for high blood pressure
de réir: Ruvolo, Antonio, et al.
Foilsithe / Cruthaithe: (2010)

Efficacy and Safety of Sacubitril/Valsartan (LCZ696) Compared With Olmesartan in Elderly Asian Patients (≥65 Years) With Systolic Hypertension
de réir: Ouppatham Supasyndh, et al.
Foilsithe / Cruthaithe: (2017)

Valsartan combination therapy in the management of hypertension – patient perspectives and clinical utility
de réir: Nash, David T, et al.
Foilsithe / Cruthaithe: (2009)

Exforge(®) (amlodipine/valsartan combination) in hypertension: the evidence of its therapeutic impact
de réir: Krzesinski, Jean-Marie, et al.
Foilsithe / Cruthaithe: (2010)

Rationale for nebivolol/valsartan combination for hypertension: review of preclinical and clinical data
de réir: Giles, Thomas D., et al.
Foilsithe / Cruthaithe: (2017)

Improvement in Retinal Capillary Rarefaction After Valsartan Treatment in Hypertensive Patients
de réir: Jumar, Agnes, et al.
Foilsithe / Cruthaithe: (2016)

An Insight Into Intestinal Microbiota of Spontaneously Hypertensive Rats After Valsartan Administration
de réir: Qi, Ying-Zi, et al.
Foilsithe / Cruthaithe: (2021)

Comparative Efficacy of Olmesartan, Losartan, Valsartan, and Irbesartan in the Control of Essential Hypertension
de réir: Oparil, Suzanne, et al.
Foilsithe / Cruthaithe: (2007)

Effects of Sacubitril/Valsartan on resistant hypertension and myocardial work in hemodialysis patients
de réir: Wang, Bin, et al.
Foilsithe / Cruthaithe: (2022)